Teleflex | TFX - Selling And Administration Expenses


Teleflex reported $222.37M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Align Technology USD 465.34M 23.67M Mar/2026
AngioDynamics USD 36.57M 3.79M Sep/2025
AtriCure USD 78.34M 109K Dec/2025
Avanos Medical USD 78.8M 1.2M Dec/2025
Baxter International USD 728M 33M Mar/2026
Becton, Dickinson and Co. USD 1.39B 27M Dec/2025
Boston Scientific USD 1.78B 53M Mar/2026
Cooper Companies USD 373.1M 46.1M Dec/2025
Dexcom USD 349.7M 49.8M Mar/2026
Edwards Lifesciences USD 522.2M 80.7M Mar/2026
General Electric Aerospace USD 1.08B 496M Mar/2026
Globus Medical USD 318.48M 4.88M Dec/2025
Haemonetics USD 109.15M 7.54M Dec/2025
Inogen USD 43.77M 510K Jun/2024
Insulet USD 331.4M 16.2M Dec/2025
Integra LifeSciences USD 156.45M 12.6M Dec/2025
Intuitive Surgical USD 613.3M 73.8M Mar/2026
J&J USD 6.03B 719M Mar/2026
Masimo USD 128M 11.6M Dec/2025
Medtronic 2.97B 159M Sep/2025
Merit Medical Systems USD 110.47M 4.36M Mar/2026
Orthofix International USD 130.35M 11.31M Dec/2025
ResMed USD 279.8M 1.4M Mar/2026
Steris USD 352.3M 2.6M Dec/2025
Stryker USD 2.15B 17M Mar/2026
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 222.37M 59.4M Dec/2025
Zimmer Biomet Holdings USD 849.9M 5.8M Mar/2026